SCHEMBL8201002

SCHEMBL8201002

CC(C)NC(=O)c1cccc(C(=O)NCc2cnn(-c3ccc4nc(-c5cccnc5)n(C)c4c3)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
BMPR2 Q13873 1/20 0.42
ADRB2 P07550 1/20 0.39
KIT P10721 3/20 0.37
NAMPT P43490 1/20 0.36
PDE2A O00408 1/20 0.36
ALDH1A1 P00352 2/20 0.35
AKT1 P31749 2/20 0.35
AKT2 P31751 2/20 0.35
AKT3 Q9Y243 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
WDR5 P61964 1/20 0.35
TSHR P16473 1/20 0.35
ELANE P08246 1/20 0.35
GRM1 Q13255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8206437 0.87 ADRB2 (0.41) BMPR2ADRB2ALDH1A1NPSR1MEN1
SCHEMBL12853419 0.85 ADRB2 (0.39) ADRB2ALDH1A1
SCHEMBL12853298 0.84 ADRB2 (0.44) ADRB2ALDH1A1NPSR1KMT2ATSHR
SCHEMBL17012020 0.83 ADRB2 (0.40) ADRB2ALDH1A1NPSR1
SCHEMBL12853417 0.83 ADRB2 (0.39) ADRB2ALDH1A1ELANE
SCHEMBL8198824 0.82 ADRB2 (0.41) ADRB2ALDH1A1MEN1KMT2AELANE
SCHEMBL8211564 0.81 ADRB2 (0.41) ADRB2ALDH1A1NPSR1ADORA2AADORA1
SCHEMBL8201496 0.81 ADRB2 (0.44) ADRB2ALDH1A1WDR5
SCHEMBL8205940 0.80 ADRB2 (0.43) ADRB2ALDH1A1NPSR1WDR5
SCHEMBL8201394 0.79 ADRB2 (0.46) ADRB2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 CYP11B1 440/4885CYP11B2 759/4885BMPR2 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.